 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
15 June 1997 | Volume 126 Issue 12 | Pages 946-954
Background: The rate of disease progression among persons infected with human immunodeficiency virus type 1 (HIV-1) varies widely, and the relative prognostic value of markers of disease activity has not been defined.
Objective: To compare clinical, serologic, cellular, and virologic markers for their ability to predict progression to the acquired immunodeficiency syndrome (AIDS) and death during a 10-year period.
Design: Prospective, multicenter cohort study.
Setting: Four university-based clinical centers participating in the Multicenter AIDS Cohort Study.
Patients: 1604 men infected with HIV-1.
Measurements: The markers compared were oral candidiasis (thrush) or fever; serum neopterin levels; serum ß2-µglobulin levels; number and percentage of CD3+, CD4+, and CD8+ lymphocytes; and plasma viral load, which was measured as the concentration of HIV-1 RNA found using a sensitive branched-DNA signal-amplification assay.
Results: Plasma viral load was the single best predictor of progression to AIDS and death, followed (in order of predictive strength) by CD4+ lymphocyte count and serum neopterin levels, serum ß2-µglobulin levels, and thrush or fever. Plasma viral load discriminated risk at all levels of CD4+ lymphocyte counts and predicted their subsequent rate of decline. Five risk categories were defined by plasma HIV-1 RNA concentrations: 500 copies/mL or less, 501 to 3000 copies/mL, 3001 to 10 000 copies/mL, 10 001 to 30 000 copies/mL, and more than 30 000 copies/mL. Highly significant (P < 0.001) differences in the percentages of participants who progressed to AIDS within 6 years were seen in the five risk categories: 5.4%, 16.6%, 31.7%, 55.2%, and 80.0%, respectively. Highly significant (P < 0.001) differences in the percentages of participants who died of AIDS within 6 years were also seen in the five risk categories: 0.9%, 6.3%, 18.1%, 34.9%, and 69.5%, respectively. A regression tree incorporating both HIV-1 RNA measurements and CD4+ lymphocyte counts provided better discrimination of outcome than did either marker alone; use of both variables defined categories of risk for AIDS within 6 years that ranged from less than 2% to 98%.
Conclusions: Plasma viral load strongly predicts the rate of decrease in CD4+ lymphocyte count and progression to AIDS and death, but the prognosis of HIV-infected persons is more accurately defined by combined measurement of plasma HIV-1 RNA and CD4+ lymphocytes.
Author and Article Information
For author affiliations and current author addresses, see end of text.
ARTICLE
Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection
Acknowledgment: The authors thank the MACS participants and staff for their dedication.
Grant Support: By the National Institute of Allergy and Infectious Diseases with supplemental support grants U01-AI-35042, 5-MO1-RR-00722 (GCRC), UO1-AI-35043, UO1-AI-37984, UO1-AI-35039, UO1-AI-35040, UO1-AI-37613, UO1-AI-35041 from the National Cancer Institute.
Requests for Reprints: John W. Mellors, MD, Graduate of School of Public Health, 603 Parran Hall, 130 DeSoto Street, University of Pittsburgh, Pittsburgh, PA 15261.
Current Author Addresses: Dr. Mellors: University of Pittsburgh, Graduate School of Public Health, 603 Parran Hall, 130 DeSoto Street, Pittsburgh, PA 15261.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  A. Holguin, M. Lopez, M. Molinero, and V. Soriano Performance of Three Commercial Viral Load Assays, Versant Human Immunodeficiency Virus Type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, Testing HIV-1 Non-B Subtypes and Recombinant Variants J. Clin. Microbiol., September 1, 2008; 46(9): 2918 - 2923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Sanders, A. M. Bayoumi, M. Holodniy, and D. K. Owens Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age Ann Intern Med, June 17, 2008; 148(12): 889 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Pandrea, R. Onanga, S. Souquiere, A. Mouinga-Ondeme, O. Bourry, M. Makuwa, P. Rouquet, G. Silvestri, F. Simon, P. Roques, et al. Paucity of CD4+ CCR5+ T Cells May Prevent Transmission of Simian Immunodeficiency Virus in Natural Nonhuman Primate Hosts by Breast-Feeding J. Virol., June 1, 2008; 82(11): 5501 - 5509. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Sieg, D. A. Bazdar, and M. M. Lederman S-phase entry leads to cell death in circulating T cells from HIV-infected persons J. Leukoc. Biol., June 1, 2008; 83(6): 1382 - 1387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E A Soria, I I Cadile, L R Allende, and L E Kremer Pharmacoepidemiological approach to the predisposing factors for highly active antiretroviral therapy failure in an HIV-positive cohort from Cordoba City (Argentina) 1995-2005 Int J STD AIDS, May 1, 2008; 19(5): 335 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Gordon, R. M. Dunham, J. C. Engram, J. Estes, Z. Wang, N. R. Klatt, M. Paiardini, I. V. Pandrea, C. Apetrei, D. L. Sodora, et al. Short-Lived Infected Cells Support Virus Replication in Sooty Mangabeys Naturally Infected with Simian Immunodeficiency Virus: Implications for AIDS Pathogenesis J. Virol., April 1, 2008; 82(7): 3725 - 3735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Shechter, M. D. Bailey, A. J. Schaefer, and M. S. Roberts The Optimal Time to Initiate HIV Therapy Under Ordered Health States Operations Research, January 1, 2008; 56(1): 20 - 33. [Abstract] [PDF]
|
|
|
|
|
|
I. Karlsson, B. Malleret, P. Brochard, B. Delache, J. Calvo, R. Le Grand, and B. Vaslin Dynamics of T-Cell Responses and Memory T Cells during Primary Simian Immunodeficiency Virus Infection in Cynomolgus Macaques J. Virol., December 15, 2007; 81(24): 13456 - 13468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Damond, B. Roquebert, A. Benard, G. Collin, M. Miceli, P. Yeni, F. Brun-Vezinet, and D. Descamps Human Immunodeficiency Virus Type 1 (HIV-1) Plasma Load Discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 Assays J. Clin. Microbiol., October 1, 2007; 45(10): 3436 - 3438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kremer, G. Ironson, N. Schneiderman, and M. Hautzinger ``It's My Body'': Does Patient Involvement in Decision Making Reduce Decisional Conflict? Med Decis Making, October 1, 2007; 27(5): 522 - 532. [Abstract] [PDF]
|
|
|
|
 |
|
 C. C McGowan, P. Cahn, E. Gotuzzo, D. Padgett, J. W Pape, M. Wolff, M. Schechter, and D. R Masys Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme Int. J. Epidemiol., October 1, 2007; 36(5): 969 - 976. [Full Text] [PDF]
|
|
|
|
 |
|
 I. V. Pandrea, R. Gautam, R. M. Ribeiro, J. M. Brenchley, I. F. Butler, M. Pattison, T. Rasmussen, P. A. Marx, G. Silvestri, A. A. Lackner, et al. Acute Loss of Intestinal CD4+ T Cells Is Not Predictive of Simian Immunodeficiency Virus Virulence J. Immunol., September 1, 2007; 179(5): 3035 - 3046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Apetrei, R. Gautam, B. Sumpter, A. C. Carter, T. Gaufin, S. I. Staprans, J. Else, M. Barnes, R. Cao Jr., S. Garg, et al. Virus Subtype-Specific Features of Natural Simian Immunodeficiency Virus SIVsmm Infection in Sooty Mangabeys J. Virol., August 1, 2007; 81(15): 7913 - 7923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Cole, M. A. Hernan, K. Anastos, B. D. Jamieson, and J. M. Robins Determining the Effect of Highly Active Antiretroviral Therapy on Changes in Human Immunodeficiency Virus Type 1 RNA Viral Load using a Marginal Structural Left-censored Mean Model Am. J. Epidemiol., July 15, 2007; 166(2): 219 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Delpierre, L. Cuzin, and F. Lert Routine testing to reduce late HIV diagnosis in France BMJ, June 30, 2007; 334(7608): 1354 - 1356. [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Mellors, J. B. Margolick, J. P. Phair, C. R. Rinaldo, R. Detels, L. P. Jacobson, and A. Munoz Prognostic Value of HIV-1 RNA, CD4 Cell Count, and CD4 Cell Count Slope for Progression to AIDS and Death in Untreated HIV-1 Infection JAMA, June 6, 2007; 297(21): 2349 - 2350. [Full Text] [PDF]
|
|
|
|
|
|
C. R. Brown, M. Czapiga, J. Kabat, Q. Dang, I. Ourmanov, Y. Nishimura, M. A. Martin, and V. M. Hirsch Unique Pathology in Simian Immunodeficiency Virus-Infected Rapid Progressor Macaques Is Consistent with a Pathogenesis Distinct from That of Classical AIDS J. Virol., June 1, 2007; 81(11): 5594 - 5606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. MacNeil, A. D. Sarr, J.-L. Sankale, S. T. Meloni, S. Mboup, and P. Kanki Direct Evidence of Lower Viral Replication Rates In Vivo in Human Immunodeficiency Virus Type 2 (HIV-2) Infection than in HIV-1 Infection J. Virol., May 15, 2007; 81(10): 5325 - 5330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mitsuyasu, R. Gelman, D. W. Cherng, A. Landay, J. Fahey, R. Reichman, A. Erice, R. P. Bucy, J. M. Kilby, M. M. Lederman, et al. The Virologic, Immunologic, and Clinical Effects of Interleukin 2 With Potent Antiretroviral Therapy in Patients With Moderately Advanced Human Immunodeficiency Virus Infection: A Randomized Controlled Clinical Trial--AIDS Clinical Trials Group 328 Arch Intern Med, March 26, 2007; 167(6): 597 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. D. Lima, R. S. Hogg, and J. S. G. Montaner Presenting Plasma HIV RNA Level and Rate of CD4 T-Cell Decline JAMA, February 28, 2007; 297(8): 805 - 806. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Corey Synergistic Copathogens -- HIV-1 and HSV-2 N. Engl. J. Med., February 22, 2007; 356(8): 854 - 856. [Full Text] [PDF]
|
|
|
|
|
|
B. Sumpter, R. Dunham, S. Gordon, J. Engram, M. Hennessy, A. Kinter, M. Paiardini, B. Cervasi, N. Klatt, H. McClure, et al. Correlates of Preserved CD4+ T Cell Homeostasis during Natural, Nonpathogenic Simian Immunodeficiency Virus Infection of Sooty Mangabeys: Implications for AIDS Pathogenesis J. Immunol., February 1, 2007; 178(3): 1680 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Sevigny, S. M. Albert, M. P. McDermott, G. Schifitto, J. C. McArthur, N. Sacktor, K. Conant, O. A. Selnes, Y. Stern, D. R. McClernon, et al. An Evaluation of Neurocognitive Status and Markers of Immune Activation as Predictors of Time to Death in Advanced HIV Infection Arch Neurol, January 1, 2007; 64(1): 97 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Paltiel, R. P. Walensky, B. R. Schackman, G. R. Seage III, L. M. Mercincavage, M. C. Weinstein, and K. A. Freedberg Expanded HIV Screening in the United States: Effect on Clinical Outcomes, HIV Transmission, and Costs Ann Intern Med, December 5, 2006; 145(11): 797 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Perrin, J. M. Pawlotsky, M. Bouvier-Alias, C. Sarrazin, S. Zeuzem, and G. Colucci Multicenter Performance Evaluation of a New TaqMan PCR Assay for Monitoring Human Immunodeficiency Virus RNA Load J. Clin. Microbiol., December 1, 2006; 44(12): 4371 - 4375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Nilsson, A. Boasso, P. A. Velilla, R. Zhang, M. Vaccari, G. Franchini, G. M. Shearer, J. Andersson, and C. Chougnet HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS Blood, December 1, 2006; 108(12): 3808 - 3817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-C. Gauduin, Y. Yu, A. Barabasz, A. Carville, M. Piatak, J. D. Lifson, R. C. Desrosiers, and R. P. Johnson Induction of a virus-specific effector-memory CD4+ T cell response by attenuated SIV infection J. Exp. Med., November 27, 2006; 203(12): 2661 - 2672. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Rodriguez, A. K. Sethi, V. K. Cheruvu, W. Mackay, R. J. Bosch, M. Kitahata, S. L. Boswell, W. C. Mathews, D. R. Bangsberg, J. Martin, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA, September 27, 2006; 296(12): 1498 - 1506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. K. Henry, P. Tebas, and H. C. Lane Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle. JAMA, September 27, 2006; 296(12): 1523 - 1525. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Goldie, Y. Yazdanpanah, E. Losina, M. C. Weinstein, X. Anglaret, R. P. Walensky, H. E. Hsu, A. Kimmel, C. Holmes, J. E. Kaplan, et al. Cost-Effectiveness of HIV Treatment in Resource-Poor Settings -- The Case of Cote d'Ivoire N. Engl. J. Med., September 14, 2006; 355(11): 1141 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ylitalo, S. Brogly, M. D. Hughes, S. Nachman, W. Dankner, R. Van Dyke, G. R. Seage III, and for the Pediatric AIDS Clinical Trials Group Proto Risk Factors for Opportunistic Illnesses in Children With Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral Therapy Arch Pediatr Adolesc Med, August 1, 2006; 160(8): 778 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A. Wilson, J. Reed, G. S. Napoe, S. Piaskowski, A. Szymanski, J. Furlott, E. J. Gonzalez, L. J. Yant, N. J. Maness, G. E. May, et al. Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239. J. Virol., June 1, 2006; 80(12): 5875 - 5885. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Yant, T. C. Friedrich, R. C. Johnson, G. E. May, N. J. Maness, A. M. Enz, J. D. Lifson, D. H. O'Connor, M. Carrington, and D. I. Watkins The High-Frequency Major Histocompatibility Complex Class I Allele Mamu-B*17 Is Associated with Control of Simian Immunodeficiency Virus SIVmac239 Replication. J. Virol., May 1, 2006; 80(10): 5074 - 5077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Onanga, S. Souquiere, M. Makuwa, A. Mouinga-Ondeme, F. Simon, C. Apetrei, and P. Roques Primary Simian Immunodeficiency Virus SIVmnd-2 Infection in Mandrills (Mandrillus sphinx). J. Virol., April 1, 2006; 80(7): 3301 - 3309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Page-Shafer, S. Sweet, S. Kassaye, and C. Ssali (C2) Saliva, Breast Milk, and Mucosal Fluids in HIV Transmission Adv. Dent. Res., April 1, 2006; 19(1): 152 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Boschi, C. Tinelli, P. Ortolani, and M. Arlotti Safety and factors predicting the duration of first and second treatment interruptions guided by CD4+ cell counts in patients with chronic HIV infection J. Antimicrob. Chemother., March 1, 2006; 57(3): 520 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Jansen, I. M. De Cuyper, B. Hooibrink, A. K. van der Bij, D. van Baarle, and F. Miedema Prognostic value of HIV-1 Gag-specific CD4+ T-cell responses for progression to AIDS analyzed in a prospective cohort study Blood, February 15, 2006; 107(4): 1427 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Hammer Clinical practice. Management of newly diagnosed HIV infection. N. Engl. J. Med., October 20, 2005; 353(16): 1702 - 1710. [Full Text] [PDF]
|
|
|
|
|
|
L. E. Riley and S. Yawetz Case records of the Massachusetts General Hospital. Case 32-2005. A 34-year-old HIV-positive woman who desired to become pregnant. N. Engl. J. Med., October 20, 2005; 353(16): 1725 - 1732. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Cole, M. A. Hernan, J. B. Margolick, M. H. Cohen, and J. M. Robins Marginal Structural Models for Estimating the Effect of Highly Active Antiretroviral Therapy Initiation on CD4 Cell Count Am. J. Epidemiol., September 1, 2005; 162(5): 471 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Swanson, C. de Mendoza, Y. Joshi, A. Golden, R. L. Hodinka, V. Soriano, S. G. Devare, and J. Hackett Jr. Impact of Human Immunodeficiency Virus Type 1 (HIV-1) Genetic Diversity on Performance of Four Commercial Viral Load Assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT J. Clin. Microbiol., August 1, 2005; 43(8): 3860 - 3868. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Chou, L. H. Huffman, R. Fu, A. K. Smits, and P. T. Korthuis Screening for HIV: A Review of the Evidence for the U.S. Preventive Services Task Force Ann Intern Med, July 5, 2005; 143(1): 55 - 73. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Gilbert and Y. Sun Failure time analysis of HIV vaccine effects on viral load and antiretroviral therapy initiation Biostat., July 1, 2005; 6(3): 374 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Hourfar, U. Michelsen, M. Schmidt, A. Berger, E. Seifried, and W. K. Roth High-Throughput Purification of Viral RNA Based on Novel Aqueous Chemistry for Nucleic Acid Isolation Clin. Chem., July 1, 2005; 51(7): 1217 - 1222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Miller Commentary: Sifting through the maze of viral and host diversity and HIV/AIDS clinical progression Int. J. Epidemiol., June 1, 2005; 34(3): 584 - 585. [Full Text] [PDF]
|
|
|
|
|
|
R. P. Walensky, M. C. Weinstein, H. E. Smith, K. A. Freedberg, and A. D. Paltiel Optimal Allocation of Testing Dollars: The Example of HIV Counseling, Testing, and Referral Med Decis Making, May 1, 2005; 25(3): 321 - 329. [Abstract] [PDF]
|
|
|
|
 |
|
 H. D. Strickler, R. D. Burk, M. Fazzari, K. Anastos, H. Minkoff, L. S. Massad, C. Hall, M. Bacon, A. M. Levine, D. H. Watts, et al. Natural History and Possible Reactivation of Human Papillomavirus in Human Immunodeficiency Virus-Positive Women J Natl Cancer Inst, April 20, 2005; 97(8): 577 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Peretz, G. Alter, M.-P. Boisvert, G. Hatzakis, C. M. Tsoukas, and N. F. Bernard Human Immunodeficiency Virus (HIV)-Specific Gamma Interferon Secretion Directed against All Expressed HIV Genes: Relationship to Rate of CD4 Decline J. Virol., April 15, 2005; 79(8): 4908 - 4917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Fernandez Ten Myths About HIV Infection and Aids Focus, April 1, 2005; 3(2): 184 - 193. [Full Text] [PDF]
|
|
|
|
|
|
G. Silvestri, A. Fedanov, S. Germon, N. Kozyr, W. J. Kaiser, D. A. Garber, H. McClure, M. B. Feinberg, and S. I. Staprans Divergent Host Responses during Primary Simian Immunodeficiency Virus SIVsm Infection of Natural Sooty Mangabey and Nonnatural Rhesus Macaque Hosts J. Virol., April 1, 2005; 79(7): 4043 - 4054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Gonzalez, H. Kulkarni, H. Bolivar, A. Mangano, R. Sanchez, G. Catano, R. J. Nibbs, B. I. Freedman, M. P. Quinones, M. J. Bamshad, et al. The Influence of CCL3L1 Gene-Containing Segmental Duplications on HIV-1/AIDS Susceptibility Science, March 4, 2005; 307(5714): 1434 - 1440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Antiretroviral Therapy Cohort Collaboration* The Changing Incidence of AIDS Events in Patients Receiving Highly Active Antiretroviral Therapy Arch Intern Med, February 28, 2005; 165(4): 416 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Sanders, A. M. Bayoumi, V. Sundaram, S. P. Bilir, C. P. Neukermans, C. E. Rydzak, L. R. Douglass, L. C. Lazzeroni, M. Holodniy, and D. K. Owens Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy N. Engl. J. Med., February 10, 2005; 352(6): 570 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Paltiel, M. C. Weinstein, A. D. Kimmel, G. R. Seage III, E. Losina, H. Zhang, K. A. Freedberg, and R. P. Walensky Expanded Screening for HIV in the United States -- An Analysis of Cost-Effectiveness N. Engl. J. Med., February 10, 2005; 352(6): 586 - 595. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Portela, I. P. R. Souza, E. M. M. B. Costa, A. N. Hagler, R. M. A. Soares, and A. L. S. Santos Differential Recovery of Candida Species from Subgingival Sites in Human Immunodeficiency Virus-Positive and Healthy Children from Rio de Janeiro, Brazil J. Clin. Microbiol., December 1, 2004; 42(12): 5925 - 5927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Transmission of Primary and Secondary Syphilis by Oral Sex--Chicago, Illinois, 1998-2002 JAMA, November 24, 2004; 292(20): 2459 - 2461. [Full Text] [PDF]
|
|
Article
